<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001381</url>
  </required_header>
  <id_info>
    <org_study_id>940098</org_study_id>
    <secondary_id>94-C-0098</secondary_id>
    <nct_id>NCT00001381</nct_id>
  </id_info>
  <brief_title>A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder</brief_title>
  <official_title>A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Patients with superficial transitional cell carcinoma of the bladder will be treated with
      intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered
      in this fashion will be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with superficial transitional cell carcinoma of the bladder will be treated with
      intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered
      in this fashion will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1994</start_date>
  <completion_date>December 2000</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>18</enrollment>
  <condition>Bladder Neoplasms</condition>
  <condition>Carcinoma, Transitional Cell</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suramin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Histologically confirmed superficial transitional cell carcinoma of the bladder
        pathologically staged as Tis, Ta, or T1. Visible tumors at time of treatment not required.
        No metastatic disease or muscle invasion.

        Clinically useful pretreatment bladder function required.

        No significant prostatic obstructive symptoms associated with impaired or incomplete
        bladder emptying.

        No active urinary tract infection.

        PRIOR/CONCURRENT THERAPY:

        At least 1 course of prior standard intravesical therapy required.

        At least 4 weeks since intravesical treatment, with resolution of any local or systemic
        toxicity.

        PATIENT CHARACTERISTICS:

        Age: 18 and over.

        Performance status: ECOG 0 or 1.

        Hematopoietic:

        WBC at least 3,300;

        Hemoglobin at least 10 g/dL.

        Hepatic:

        Bilirubin no greater than 1.5 mg/dL;

        AST and ALT no greater than 2 times normal.

        Renal: Creatinine no greater than 1.5 mg/dL.

        OTHER:

        Medically able to undergo cystoscopy.

        No pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gansler T, Vaghmar N, Olson JJ, Graham SD. Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures. J Urol. 1992 Sep;148(3):910-4.</citation>
    <PMID>1512858</PMID>
  </reference>
  <reference>
    <citation>Walther MM, Figg WD, Linehan WM. Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J Urol. 1996;14 Suppl 1:S8-11. Review.</citation>
    <PMID>8738403</PMID>
  </reference>
  <reference>
    <citation>Walther MM, Trahan EE, Cooper M, Venzon D, Linehan WM. Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines. J Urol. 1994 Nov;152(5 Pt 1):1599-602.</citation>
    <PMID>7933214</PMID>
  </reference>
  <verification_date>January 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Adult</keyword>
  <keyword>Intravesical Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suramin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

